SURF Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 sep 2023 @ 22:00):

Stats
Dagens volum	1.46M
Gjennomsnittsvolum	798 146
Markedsverdi	65.08M
EPS	$0 ( 2024-05-02 )
Neste inntjeningsdato	( $0 ) 2024-07-31
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.686
ATR14	$0.0570 (5.33%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-08	Sigal Charles Elliott	Sell	45 453	Common Stock
2023-09-08	Sigal Charles Elliott	Sell	113 636	Stock Option (Right to Buy)
2023-09-08	Adams Chandra	Sell	23 884	Common Stock
2023-09-08	Adams Chandra	Sell	50 000	Stock Option (Right to Buy)
2023-09-08	Rath Henry C.	Sell	44 971	Common Stock

INSIDER POWER
-73.79
Last 94 transactions
Buy: 4 462 585 \| Sell: 5 534 482

Volum Korrelasjon

Lang: 0.03 (neutral)

Kort: 0.31 (neutral)

Signal:(61.247) Neutral

Surface Oncology Inc Korrelasjon

10 Mest positive korrelasjoner
TETC	0.936
SGEN	0.935
SGIIU	0.935
VLAT	0.935
ADAL	0.934
MSDAU	0.933
BRIV	0.932
VMGA	0.93
APXI	0.929
AFAR	0.928

10 Mest negative korrelasjoner
MSEX	-0.948
GPRO	-0.945
RVSB	-0.941
JJSF	-0.941
IMBI	-0.939
MKTW	-0.939
AVXL	-0.938
TBLT	-0.936
TSBK	-0.933
NYMT	-0.931

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Surface Oncology Inc Korrelasjon - Valuta/Råvare

0.62
( weak )

0.79
( moderate )

0.00
( neutral )

0.46
( neutral )

-0.50
( neutral )

-0.61
( weak negative )

Surface Oncology Inc Økonomi

Annual	2022
Omsetning:	$30.00M
Bruttogevinst:	$30.00M (100.00 %)
EPS:	$-1.170

FY	2022
Omsetning:	$30.00M
Bruttogevinst:	$30.00M (100.00 %)
EPS:	$-1.170

FY	2021
Omsetning:	$2.69M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.735

FY	2020
Omsetning:	$126.16M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$1.670

Financial Reports:

No articles found.

Surface Oncology Inc

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.